PayPay and Alipay+ Extend Enhanced E-Wallet Payment Options to Over 3 Million Merchants Across Japan With Expanded Partnership
At the Singapore FinTech Festival 2024, PayPay, Japan's top QR payment operator, today announced an expanded partnership with Alipay+, Ant International’s cross-border mobile payment and digitalisation technology solution, broadening its merchant coverage network across Japan. By working with local partners including PayPay, Alipay+ will now connect over 3 million local merchants to the global payment ecosystem, enabling local businesses and payment partners to provide global visitors seamless and secure payment and travel experiences with their preferred domestic e-wallets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105682881/en/
Travellers can use Alipay+ wallets to scan the PayPay QR code for payment at the vast majority of PayPay stores. (Photo: Business Wire)
Through this expanded partnership, travellers using Alipay+ payment partner apps will be able to scan PayPay QR codes to make payments at a wide range of merchant-presented mode (MPM) stores across Japan, even if the merchants have not yet displayed Alipay+ point of sale materials. They can also look forward to special promotions during the upcoming Christmas and New Year travel peak seasons. Alipay+ will collaborate with PayPay merchants to launch a promotional campaign, which will run from December 20, 2024 to January 10, 2025.
Users of participating payment partners, including Alipay, AlipayHK, GCash, Kakao Pay, Toss Pay, Touch 'n Go eWallet, and TrueMoney, will be offered an exclusive 10% discount (up to a maximum of JPY 1,000, CNY 50). Tinaba will also provide a 10% cashback promotion (up to a maximum of EUR 20). Eligible users may redeem the offer once during the campaign period.
Alipay+’s current partner payment app network in Japan includes 16 e-wallets and bank apps, such as Alipay (Chinese mainland), AlipayHK (Hong Kong SAR China), MPay (Macao SAR China), South Korea’s Kakao Pay, Naver Pay and Toss, Singapore’s OCBC Digital, Changi Pay and EZ-Link, Malaysia’s Touch ‘n Go eWallet and MyPB by Public Bank Berhad, the Philippines’ GCash and HelloMoney, TrueMoney (Thailand), Hipay (Mongolia), and Tinaba (Italy).
Catering to the rising demand for “in-depth tourism” with seamless experiences
Japan ranks as the top tourist destination in the Asia-Pacific region for tourists globally, according to the World Economic Forum’s latest data1. As inbound visitors grow steadily, local merchants benefit from staying responsive to the evolving preferences of international tourists.
Many tourists are now exploring beyond popular cities like Tokyo, Osaka and Kyoto, seeking the unique charm of lesser-known regions. They want seamless cross-border payment experiences similar to those in their home markets. Alipay+ supports this by expanding its merchant coverage to include a growing number of SMEs, enabling tourists to access unique travel experiences.
All-in-one payments are also reshaping consumer preferences and behavior, with travelers spending more on localised experiences rather than just retail purchases. The number of travelers using their home payment apps to pay via Alipay+ in Japan nearly doubled from January 1 to October 31 2024, compared to the same period last year. The total transactions made through Alipay+ partner payment apps in the first ten months of 2024 nearly tripled year over year. Notably, food & beverage and entertainment have emerged as the top categories for Alipay+ transactions in the first ten months, alongside retail.
Unlocking global opportunities for local SMEs
Alipay+ connects over 3 million merchants, including a significant number of SMEs through its partnership with PayPay. These vibrant businesses are spread across the country, ranging from popular snack shops and anime merchandise stores to guesthouses near Mount Fuji. By collaborating with PayPay, Alipay+ simplifies payments for tourists while helping local merchants tap into the growing tourism market and support regional economies.
E-wallet partners and merchants also collaborate with Alipay+ to enhance consumer engagement through marketing initiatives. Over 20 brands run campaigns with Alipay+, offering users of Alipay+ partner e-wallets discounts at about 300,000 merchants across Japan, including airport shops, department stores, electronics and appliances retailers, health and beauty shops, convenience store chains, and premium shopping malls.
To unlock more growth opportunities for local businesses, Alipay+ is continually expanding its partner network and now connects 90 million merchants in 66 countries and regions to 1.6 billion consumer accounts on 35 mobile payment partners. Alipay+’s extensive regional partnerships, including those with national QR schemes, also foster inclusive growth for SMEs. These include Singapore’s SGQR, Malaysia’s PayNet, South Korea’s ZeroPay, Sri Lanka's LankaPay and Cambodia's KHQR.
Masayoshi Yanase, Corporate Officer, Division Head, Finance Business Strategy Division, PayPay Corporation, said: “PayPay is committed to building a connected, seamless payment ecosystem that empowers local businesses to connect with international travellers. Through convenient and secure payment solutions, we enhance the travel experience for global tourists. Together with Alipay+, we aim to contribute to economic growth across Japan by supporting digital transactions for businesses of all sizes, from bustling city centers to emerging regional destinations.”
Douglas Feagin, President of Ant International, said: “The simplicity of QR code payment is proving to be a game changer for the future of travel. Together with our partners like PayPay, we are powering inclusive economic growth by connecting the vibrant supply chain of Japan's nationwide merchants to the growing demand of international consumers for hyper-local experiences via the global payment ecosystem with Alipay+. Enabling travellers to pay with their home wallets when they see a PayPay QR code will open up the payment borders for the global tourism marketplace.”
About PayPay
PayPay Corporation offers the cashless payment service "PayPay," expanding nationwide from large chains to small businesses, vending machines, taxis, and public transportation. It can be used for various payments, including online services and utility bills. Users can transfer and receive PayPay balances (PayPay Money and PayPay Money Lite) without fees, exchange PayPay Points for points from partner businesses, and even experience simulated investments. Additionally, a 24/7 support hotline and a compensation system provide users with a secure environment for worry-free usage.
About Alipay+
Alipay+ is a suite of cross-border mobile payment and digitalisation technology solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while travelling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105682881/en/
Contacts
Media Inquiries:
Ant International
Janice Chen
janicechen.cyh@antgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom